Comparing congenital pneumonia and transient tachypnea in newborns
The Value of Systemic Inflammation Markers in Differentiating Congenital Pneumonia From TTN in Neonates
This study is trying to see if certain blood tests can help doctors tell the difference between two breathing problems in newborns, so they can give the right treatment and avoid using antibiotics when they’re not needed.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 35 (estimated) |
| Ages | 1 Hour to 24 Hours |
| Sex | All |
| Sponsor | Dr. Behcet Uz Children's Hospital Academic / other |
| Locations | 1 site (İzmir, Konak) |
| Trial ID | NCT06803355 on ClinicalTrials.gov |
What this trial studies
This observational study aims to differentiate between transient tachypnea of the newborn (TTN) and congenital pneumonia in neonates by assessing inflammatory markers such as the Systemic Immune-Inflammation Index (SII) and the Systemic Immune-Response Index (SIRI). Conducted at Dr. Behçet Uz Children's Hospital, the study will analyze patients admitted for respiratory distress within the first 24 hours after birth. Data collected will include clinical parameters, laboratory results, and treatment details to evaluate the effectiveness of these biomarkers in guiding appropriate treatment and reducing unnecessary antibiotic use.
Who should consider this trial
Good fit: Ideal candidates for this study are neonates born at or after 37 weeks of gestation who are admitted with respiratory distress and a preliminary diagnosis of TTN.
Not a fit: Patients with congenital anomalies, genetic syndromes, or those diagnosed with sepsis will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic accuracy and treatment for newborns with respiratory distress, minimizing complications and antibiotic misuse.
How similar studies have performed: While the use of inflammatory markers in neonatal respiratory conditions is being explored, this specific approach to differentiate TTN from congenital pneumonia is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Neonates born at ≥37 weeks of gestation, Admitted within the first 24 hours after birth with respiratory distress and a preliminary diagnosis of TTN Exclusion Criteria: * Congenital anomalies Genetic syndromes Diagnosis of sepsis Patients without informed consent
Where this trial is running
İzmir, Konak
- Dr. Behçet Uz Children's Hospital — İzmir, Konak, Turkey (Recruiting)
Study contacts
- Study coordinator: Şebnem Çalkavur, MD
- Email: sebnemcalkavur@yahoo.com
- Phone: +902324116000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.